美国密歇根大学招聘药物化学博士后

Postdoctoral position is available to develop small molecule inhibitors for targeted therapies in cancer. We are seeking for highly motivated postdoctoral fellow with very extensive knowledge and experience in medicinal chemistry and synthetic organic chemistry. The candidate will be involved in designing and synthesis of small molecule inhibitors targeting proteins as potential anti-cancer agents with a major focus on synthesis of heterocyclic compounds targeting protein-protein interactions relevant to cancer. The duties will include design and synthesis of new analogues of existing leads to develop SAR for different classes of lead compounds. The successful candidate must be independent in designing synthetic routes, solving challenging synthetic problems, efficient in synthesizing targeted molecules, analyzing results and SAR data to improve drug-like properties of synthesized compounds. The applicant needs to be experienced in using HPLC, NMR and MS for organic chemistry applications. Successful candidate will be a part of an interdisciplinary team whose research is focused on different stages of pre-clinical development of anti-cancer drug candidates, including biochemical studies, medicinal chemistry, structural biology, molecular modeling, cell-based experiments and animal studies.

Requirements
Applicant must have PhD in medicinal chemistry or organic chemistry. This position requires extensive experience and independence in designing synthetic routes for new classes of compounds, solving challenging synthetic problems, development of analogues for selected leads and SAR analysis. In addition expertise in molecular modeling, structure-based drug design and ADMET optimization would be a plus. Applicant needs an expertise in using HPLC, NMR and MS for organic chemistry applications. Furthermore, excellent verbal and written communication skills in English are required.

How to apply:
Please submit cover letter, CV, and contact information for 2-3 references combined into one PDF file by e-mail.

Contact: Jolanta Grembecka, PhD
Assistant Professor
Department of Pathology
University of Michigan
4510 W. Medical Center Drive, MSRB I, 4510D
Ann Arbor, MI, 48109, USA
e-mail: jolantag@med.umich.edu

Relevant publications:
1. Grembecka J, et al., Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. (2012) Jan 29;8(3):277-84.
2. A. Shi, et al., Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood, (2012), 120, 4481-9.
3. S. He, et a.l, High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein-Protein Interaction., J. Med. Chem., 2014, Feb. 6 [Epub ahead of printing]….